Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple... Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma.
- Mechanism
- Curator reviewed
Unlike many kinase inhibitors that only target vascular endothelial growth factor (VEGF), Dovitinib inhibits receptors in the fibroblast growth factor (FGF) pathway, as well as VEGF and platelet-derived growth factor (PDGF). FGF receptor tyrosine kinase inhibition is potentially of therapeutic significance to a group of myeloma patients whose cancer cells express high levels of surface FGF receptors.
- Primary indication
- Investigated for use/treatment in multiple myeloma and solid tumors.Curator reviewed
- Formula / weight
- C21H21FN6O · 392.438 g/mol (avg)
- Code names
- TKI-258
Resolves to
PIQCTGMSNWUMAF-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2FWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Dovitinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account